Cardiff Oncology, Inc. (CRDF) vs MediciNova, Inc. (MNOV)

A side-by-side comparison of Cardiff Oncology, Inc. and MediciNova, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CRDF vs MNOV

growth of $100 · dividends reinvested · last 10y
CRDF -99.6% (-43.1%/yr)MNOV -76.5% (-13.5%/yr)MNOV compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $10020182020202220242026$0$23
CRDF MNOV

CRDF vs MNOV: by the numbers

  • •MNOV is the larger company ($82M vs $82M market cap).
  • •Both run net losses; MNOV's is the smaller (-1168.20% vs -7884.06% net margin).
  • •CRDF grew revenue faster over the past five years (5.15% vs -25.46% CAGR).

Metrics side by side

Valuation

MetricCRDFMNOV
P/S ratio161.5889.30
P/B ratio3.092.21

Profitability

MetricCRDFMNOV
Gross margin100.00%7.58%
Operating margin-8256.32%-3242.47%
Net margin-7884.06%-1168.20%
ROE-150.95%-28.85%
ROIC-159.30%-31.62%

Growth (annualized)

MetricCRDFMNOV
Revenue CAGR (5Y)5.15%-25.46%
Total return CAGR (5Y)-30.36%-13.62%

Frequently asked

Which has grown faster, CRDF or MNOV?
Over the past five years, CRDF grew revenue faster — CRDF at a 5.15% CAGR versus MNOV at -25.46%.
How have CRDF and MNOV total returns compared?
Over the past 10 years, CRDF delivered -43.20% and MNOV delivered -13.11% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.